A4GNT Antibody

What is A4GNT and why is it important in research?

A4GNT (alpha-1,4-N-acetylglucosaminyltransferase) is an enzyme that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans, forming a distinctive glycan structure represented as GlcNAcalpha1-->4Galbeta-->R . This enzyme plays a critical role in O-glycan biosynthesis pathways and has been implicated in various physiological and pathological processes. The importance of A4GNT in research stems from its tissue-biased expression pattern, with particularly high expression in the stomach (RPKM 9.5) and duodenum (RPKM 0.9) . This specific expression pattern suggests specialized functions in gastric and intestinal tissues, making it a valuable target for research in gastrointestinal biology, pathology, and glycobiology. Understanding A4GNT's role in normal and disease states can provide insights into tissue-specific glycosylation patterns and their biological significance.

What are the key specifications of commercially available A4GNT antibodies?

Commercially available A4GNT antibodies come with specific characteristics researchers should consider when selecting the appropriate reagent for their experiments. The Proteintech antibody (22670-1-AP) is a rabbit polyclonal IgG that targets A4GNT in Western blot, immunohistochemistry, and ELISA applications, with demonstrated reactivity against human, mouse, and rat samples . This antibody was developed using an A4GNT fusion protein (Ag18432) as the immunogen . The R&D Systems antibody (AF8555) is also a rabbit polyclonal antibody that recognizes the human alpha-1,4-N-Acetylglucosaminyltransferase 4/A4GNT, specifically amino acids Leu25-Lys340 with the accession number Q9UNA3 . The observed molecular weight of A4GNT in experiments ranges from 34-37 kDa, which is slightly lower than the calculated molecular weight of 39 kDa for the 340 amino acid protein . This information is crucial for proper interpretation of experimental results and validation of antibody specificity.

In which applications can A4GNT antibodies be reliably used?

A4GNT antibodies have been validated for multiple research applications with specific recommended dilutions. For Western blot (WB) applications, the recommended dilution range is 1:500-1:1000 . The antibodies have been successfully tested in detecting A4GNT in various samples including K-562 cells, mouse pancreas tissue, mouse stomach tissue, rat stomach tissue, and L02 cells . For immunohistochemistry (IHC) applications, the recommended dilution range is 1:50-1:500, with successful detection in human stomach cancer tissue, human pancreas cancer tissue, rat stomach tissue, mouse stomach tissue, and normal human stomach tissue . When performing IHC, antigen retrieval with TE buffer pH 9.0 is suggested, although citrate buffer pH 6.0 may be used as an alternative . Additionally, ELISA applications have been validated, although specific dilution recommendations are not provided in the search results. Researchers should note that optimal dilutions may vary depending on the specific experimental conditions and sample types, necessitating titration in each testing system.

How should I optimize Western blot protocols for A4GNT detection?

Optimizing Western blot protocols for A4GNT detection requires careful consideration of several experimental parameters. Based on published research, A4GNT is detected at approximately 45 kDa under reducing conditions using PVDF membranes . For optimal results, researchers should begin with the recommended antibody dilution of 1:500-1:1000 , but may need to adjust based on their specific samples and detection system. When designing your experiment, consider using positive control samples such as K-562 cells, mouse pancreas or stomach tissue, rat stomach tissue, or L02 cells, which have been validated for A4GNT detection . For the detection system, HRP-conjugated secondary antibodies have been successfully used, specifically Anti-Rabbit IgG Secondary Antibody (such as catalog # HAF008 mentioned in the R&D Systems protocol) . Reducing conditions and appropriate buffer systems (such as Immunoblot Buffer Group 1 used in the R&D Systems protocol) are important for successful detection . If band intensity is weak, consider longer exposure times, increased antibody concentration, or enhanced chemiluminescence detection systems. For quantitative analysis, always include appropriate loading controls and consider the use of fluorescent secondary antibodies for more accurate quantification.

What are the critical considerations for immunohistochemistry using A4GNT antibodies?

When performing immunohistochemistry (IHC) with A4GNT antibodies, several critical factors must be addressed to ensure reliable and reproducible results. Antigen retrieval is particularly important—it is recommended to use TE buffer at pH 9.0, although citrate buffer at pH 6.0 can serve as an alternative . The optimal antibody dilution range for IHC applications is 1:50-1:500 , but researchers should titrate the antibody concentration for their specific tissue samples and detection systems. A4GNT antibodies have been successfully used for IHC in multiple tissue types including human stomach cancer tissue, human pancreas cancer tissue, rat stomach tissue, mouse stomach tissue, and normal human stomach tissue . When designing experiments, include both positive and negative controls to validate staining specificity. For positive controls, consider using tissues with known high A4GNT expression such as stomach or pancreatic tissues. For negative controls, either omit the primary antibody or use tissues known to lack A4GNT expression. The detection system should be optimized based on the expected expression level and the desired sensitivity. For low-abundance targets, consider using amplification methods such as tyramide signal amplification. Finally, when analyzing results, pay careful attention to subcellular localization patterns, as A4GNT is typically localized to the Golgi apparatus in secretory cells.

How do I determine the appropriate sample preparation methods for A4GNT analysis?

Sample preparation is critical for successful A4GNT analysis and should be tailored to both the sample type and the analytical method. For protein extraction from tissues or cells for Western blot analysis, use lysis buffers containing appropriate detergents (such as RIPA or NP-40 based buffers) supplemented with protease inhibitors to prevent degradation of the target protein. Since A4GNT is a glycosyltransferase typically located in the Golgi apparatus, consider using fractionation methods to enrich for membrane and organelle proteins if detection sensitivity is an issue. For tissue samples intended for immunohistochemistry, proper fixation is essential—paraformaldehyde or formalin fixation followed by paraffin embedding is commonly used, but fixation time should be optimized to preserve antigenicity while maintaining tissue morphology. Fresh frozen sections may provide better antigen preservation for certain applications. When working with cell cultures, consider the growth conditions and confluency, as these factors may affect A4GNT expression levels. For RNA analysis of A4GNT expression, standard RNA extraction protocols are generally applicable, but special attention should be paid to tissue-specific optimization, particularly for stomach and duodenum samples where A4GNT is highly expressed . In all cases, sample handling should minimize the time between collection and processing to preserve protein integrity and activity.

How do I validate the specificity of A4GNT antibody signal in my experiments?

Validating antibody specificity is crucial for ensuring reliable experimental results. For A4GNT antibodies, multiple validation approaches should be employed. First, compare the observed molecular weight with the expected size—A4GNT has a calculated molecular weight of 39 kDa (340 amino acids) but is typically observed at 34-37 kDa in experimental conditions . The R&D Systems antibody detects A4GNT at approximately 45 kDa , so slight variations in observed molecular weight may occur depending on the antibody used and the sample conditions. Second, use positive and negative control samples—positive controls should include tissues with known A4GNT expression such as stomach and duodenum tissues, while negative controls could include tissues with minimal A4GNT expression or samples where the primary antibody has been omitted. Third, consider using genetic approaches such as siRNA knockdown or CRISPR knockout of A4GNT to confirm specificity, comparing the signal between wildtype and knockout samples. Fourth, competition assays using the immunizing peptide can help confirm signal specificity—pre-incubating the antibody with excess immunizing peptide should diminish or eliminate specific signals. Finally, orthogonal detection methods such as mass spectrometry or RNA expression analysis (qPCR, RNA-seq) can provide additional validation by confirming A4GNT expression in samples showing positive antibody signals.

What are common pitfalls in A4GNT antibody experiments and how can I address them?

Researchers frequently encounter several challenges when working with A4GNT antibodies. One common issue is weak or absent signal in Western blots or IHC, which may be addressed by optimizing antibody concentration, incubation time, or antigen retrieval methods. For IHC specifically, the suggested antigen retrieval with TE buffer pH 9.0 should be tried before attempting alternative methods . Another common pitfall is non-specific binding, which can manifest as multiple bands in Western blots or background staining in IHC. This issue may be mitigated by increasing blocking reagent concentration, using alternative blocking agents (BSA, milk, or commercial blockers), or adjusting antibody dilution. Cross-reactivity with other glycosyltransferases can also occur due to structural similarities—validation in multiple experimental systems and comparison with mRNA expression data can help confirm specificity. Inconsistent results between experiments may stem from variability in sample handling, so standardizing protocols for sample collection, storage, and preparation is essential. For quantitative analyses, the dynamic range of detection may be limited, requiring careful optimization of exposure times in Western blots or imaging parameters in IHC. Finally, when comparing results across species, be aware that although the A4GNT antibodies mentioned show reactivity to human, mouse, and rat samples , there may be species-specific differences in epitope recognition or expression patterns.

How should I interpret discrepancies between A4GNT protein detection and mRNA expression data?

Discrepancies between protein detection and mRNA expression are common in molecular biology and can arise from multiple biological and technical factors. When analyzing A4GNT, remember that post-transcriptional regulation may significantly impact protein levels independent of mRNA abundance. A4GNT is known to have tissue-biased expression, particularly in the stomach (RPKM 9.5) and duodenum (RPKM 0.9) , but protein levels may not directly correlate with these mRNA expression values. Protein turnover rates and stability can also contribute to differences—A4GNT may have tissue-specific post-translational modifications or degradation pathways that affect its half-life. Technical factors can also contribute to apparent discrepancies: antibody sensitivity and specificity limitations may result in false negatives where protein is present but below detection limits, or mRNA detection methods may have different sensitivity thresholds compared to protein detection methods. Additionally, consider the subcellular localization of A4GNT—as a glycosyltransferase, it is typically localized to the Golgi apparatus, which may affect extraction efficiency in certain sample preparation methods. To address these discrepancies, employ multiple detection methods (e.g., different antibodies, different detection techniques) and correlate with functional assays when possible. Temporal differences in expression should also be considered, as mRNA and protein levels may peak at different times following stimulation or during developmental processes.

What advanced computational methods can enhance A4GNT antibody research?

Advanced computational methods can significantly enhance research involving A4GNT antibodies, particularly when integrated with experimental data. Researchers can leverage epitope prediction algorithms to better understand the binding properties of A4GNT antibodies, similar to the contrastive learning approaches described for other antibodies in recent literature . These methods have shown substantial improvements over existing approaches, achieving a five-fold increase in average precision for overlapping-epitope prediction . Structure prediction tools like AlphaFold can generate models of A4GNT protein structure, helping researchers visualize potential epitopes and binding sites for antibodies. The sequence information from A4GNT (Accession # Q9UNA3 ) can serve as input for these analyses. Machine learning approaches can be employed to analyze large datasets of A4GNT expression across different tissues or disease states, potentially revealing patterns not apparent through conventional analysis. For researchers conducting high-throughput studies, automation of image analysis for IHC or immunofluorescence can provide more objective quantification of A4GNT expression patterns. Network analysis algorithms can help place A4GNT in the context of broader glycosylation pathways, potentially identifying key regulatory nodes or disease-associated perturbations. Finally, integrating antibody-based experimental data with multi-omics datasets (genomics, transcriptomics, proteomics, glycomics) can provide a more comprehensive understanding of A4GNT's role in normal physiology and disease states, helping researchers develop more targeted hypotheses for future investigation.

How can I leverage A4GNT antibodies in single-cell analysis techniques?

Single-cell analysis techniques represent a frontier in biomedical research, and A4GNT antibodies can be effectively incorporated into these methodologies to yield novel insights. For single-cell immunofluorescence or imaging mass cytometry, A4GNT antibodies can be used to examine the heterogeneity of glycosyltransferase expression within tissues, particularly in the stomach and duodenum where A4GNT expression is highest . This approach can reveal cell-type specific expression patterns and potential correlations with differentiation states or pathological changes. In single-cell proteomics, A4GNT antibodies can be employed in microfluidic antibody capture techniques to quantify expression levels across individual cells within a population. For spatial transcriptomics integrated with protein detection, researchers can combine in situ hybridization for A4GNT mRNA with antibody-based protein detection to examine the correlation between transcription and translation at the single-cell level. Advanced multiplexing techniques, such as cyclic immunofluorescence or CODEX, allow for the simultaneous detection of A4GNT alongside dozens of other markers, enabling comprehensive phenotyping of cells expressing this glycosyltransferase. For functional studies at the single-cell level, researchers can combine A4GNT antibodies with activity-based probes for glycosyltransferases to correlate expression with enzymatic activity. When implementing these techniques, researchers should carefully optimize antibody concentrations to ensure specificity at the single-cell level, and validation with multiple antibodies or orthogonal methods is particularly important given the technical challenges of single-cell analysis.